GRIFOLS ITALY operating for over 15 years in the distribution of plasma-derived products in our country, having already achieved a leading position in the Italian market.
Ethics and quality of service are the main theme of our business in Italy and in the world, since 1940 in the service of health workers and patients users of our drugs.
Our mission is to bring to Italy all Proteins Plasma derivatives produced in large and modern plants of Parets (Spain) and Los Angeles (USA) and in new plants that will soon be added, with continual improvements in yield, purity and safety and introducing those innovative, currently under research and development.
The Group Grifols collects high quality human plasma through its FDA Approved US centers plasmapheresis .
We provide the Hospital Pharmacies systems for the distribution and monitoring of drugs (Kardex), modular cleanrooms (Misterium®), equipment for the preparation of sterile infusion solutions and products for oncology (Gri-fill® 3.0) and equipment single-dose packaging of drugs destined, in hospital administration, at the bedside (Blispack).
We provide blood and plasma centers bags and equipment for transfusion, the MB-VIP service (methylene Blue Virus Inactivated Plasma) and Advanced technologies for inactivation of pathogens (viruses and bacteria) of platelet concentrates as exclusive distributors for Italy Cerus Intercept technology Inc. This technology provides the advantage to the Italian transfusion centers can also be used for virusinattivazione “in house” Plasma distributed transfusion purposes. In addition we provide medicine Transfusion Italian simple systems and efficient traceability of the transfusion of blood and plasma (Gricode®) with the benefit cost / benefit truly competitive
Contact
GRIFOLS ITALIA, S.p.A.
Via Torino, 15
56010 Vicopisano (PI)
ITALY
Tel: +39 050 87 55 111
Fax: +39 050 87 98 84
E-mail: italia@grifols.com
Web: grifols.com
Francesco Carugi, Managing Director at Grifols Italy, discusses the company’s presence in the plasma, plasma products and plasma diagnostics segments, the impact of the liberalization of the Italian plasma market on…
The European Union is in the midst of the biggest shake-up of its pharmaceutical rulebook in a generation, racing to secure supply chains, speed up drug development, and keep Europe…
Top recent stories from Italian pharma, including Angelini’s EUR 150 million EU collaboration for European health startups, Chiesi’s new deals for enzyme replacement therapies and gene editing, and why Menarini…
Writing in the June 2025 edition of DIA’s Global Forum Magazine, Finn McCartney, Maria Dutarte, Petra Adámková, and Paola Kruger from the European Patients’ Academy on Therapeutic Innovation (EUPATI) weigh…
Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the…
A roundup of some of the biggest pharma and healthcare stories coming out of Italy, including the country’s ever-falling birth rate; Chiesi’s new manufacturing investment; Doc Generici’s rebrand to DOC…
Some of the biggest pharma and healthcare stories coming out of Italy, including Italy’s antitrust investigation of Novartis and Genentech; Johnson & Johnson’s EUR 125 million investment in its Italian…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
See our Cookie Privacy Policy Here
